Introduction
Gonadotropin-releasing hormone agonists (GnRH agonists) are widely recognised as an effective treatment for patients with moderate to severe symptomatic endometriosis. In addition, the role of GnRH antagonists is being explored. GnRH analogues act by modifying the release of follicle-stimulating hormone (FSH) and luteinising hormone (LH), thereby suppressing ovarian estradiol production. GnRH agonists are effective in reducing endometriosis-associated pain but are associated with estrogendeprivation-related side effects such as hot flushes, loss of libido and loss of bone mass. 1 As new treatments are developed it will be important to understand how their efficacy and safety compare to those treatments already widely prescribed.
Aims and objectives
The purpose of this systematic literature review was to determine the feasibility of conducting a network meta-analysis of treatments for patients with moderate to severe symptomatic endometriosisassociated pain. Treatments included GnRH analogues in direct comparisons or against placebo or other pharmacological treatment.
Methods
A systematic literature review was conducted following the Centre for Reviews and Dissemination and PRISMA guidelines for systematic reviews. 2, 3 Medline, Medline In-Process Citations & Daily Update, Embase, and the Cochrane Central Register of controlled trials were searched (database inception until 24 January 2014). Randomized controlled trials (RCTs) published in English were identified that compared GnRH agonists or antagonists (Table 1) by any route of administration with placebo or any other pharmacological agent in the treatment of patients with moderate or severe endometriosisassociated pain, ideally confirmed by laparoscopy. Additional sources of literature and unpublished studies were searched, including Web of Science and NIH Clinicaltrials.gov. Titles and abstracts of search results were reviewed against the inclusion and exclusion criteria ( Table 2) . Quality assessment of RCTs was carried out according to criteria for assessment of risk of bias suggested by the Centre for Reviews and Dissemination 2 ( Table 3 ). Studies that were evaluated as having a high risk of bias and those lacking relevant data amenable to quantitative analysis were excluded from the analysis. 
Table 3: Centre for Reviews and Dissemination assessment of risk of bias in RCT
• Was randomisation carried out appropriately?
• Was the concealment of treatment allocation adequate?
• Were the groups similar at the outset of the study in terms of prognostic factors, for example, severity of disease?
• Were the care providers, participants and outcome assessors blind to treatment allocation? If any of these people were not blinded, what might be the likely impact on the risk of bias (for each outcome)? • Were there any unexpected imbalances in drop-outs between groups? If so, were they explained or adjusted for?
• Is there any evidence to suggest that the authors measured more outcomes than they reported? • Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were appropriate methods used to account for missing data?
Results

Study selection
After removing duplicates, the titles and abstracts of 1,670 records were screened and 127 were selected for full text review ( Figure 1 ). Sixty nine papers relating to 62 studies were identified as relevant. Of these, 27 studies provided data amenable to quantitative analysis (Table 4) . Two additional ongoing studies examining a treatment in development also were included. 
GnRH, Gonadotropin-releasing hormone.
Reasons for exclusion
The full publications of the 62 studies were assessed for risk of bias. Twenty seven studies were judged to have low or moderate risk of bias and 14 were judged to be at high risk of bias. A further 21 were excluded because data required for a network meta-analysis were unavailable (for example conference abstracts and/or publications that reported either no quantitative data or reported data as bar charts without estimates and confidence intervals).
Reported outcomes
Relevant reported outcomes included disease symptoms (which included an assessment of pelvic pain) and disease severity ( Nearly all of the studies measured pelvic pain in some way, most commonly along with other key symptoms of endometriosis. Twelve studies used a mB&B score to measure disease symptoms. A further six studies used a total pelvic symptom score. A further four studies measured pelvic pain using a VAS. HRQoL was measured in seven studies, most commonly by the SF-36 (n=4). The EHP-30 is the only disease-specific HRQOL instrument validated in patients with endometriosis and was used in two studies.
Adverse event reporting varied between studies. The most extensive recording used daily symptom scoring by the patient on vaginal bleeding, vasomotor symptoms, vaginal dryness, mood changes, breast tenderness, peripheral oedema and abdominal distensions.
Feasibility assessment
In order to carry out a network meta-analysis the studies included should have similar baseline population characteristics and measure similar outcomes.
An evaluation of baseline population characteristics between the 27 studies revealed that a number of studies using similar tools to measure disease staging and disease symptom severity had similar baseline population characteristics and could potentially be compared in a network meta-analysis. Disease symptom severity at baseline was assessed by the mB&B in the majority of studies. The mB&B is a physician-completed questionnaire measuring disease symptoms based on patient interview referring to the previous 4 weeks. The mB&B score is based on symptoms of dysmenorrhoea, dyspareunia and pelvic pain each scored by the patient on a scale ranging from none (0 point), minimal (1 point), moderate (2 points) or severe (3 points). To add a "clinical summary rating", physical findings of pelvic tenderness and indurations are each scored by the physician, ranging from: none (0 point), minimal (1 point), moderate (2 points) or severe (3 points). The sum of these five variables (scores) gives the total pelvic symptom score. The majority of studies included patients with mainly severe disease symptom severity.
An assessment of outcome measures used in each of the 27 studies revealed that two-thirds of the studies used the mB&B, or a variation of it, to assess improvement in disease symptoms. However, the five elements that make up the tool were not always reported in a consistent way across studies. Some trials reported a combined score of all five elements, or as clinician-reported elements, or as patient-reported elements, or as each of the five elements separately. This created variation in how change from baseline in disease symptoms was evaluated. Some studies reported change from baseline individually for dysmenorrhea, pelvic pain, dyspareunia (subjective score), and physical findings of pelvic tenderness and indurations (physician score), or these two scores were combined to create a total pelvic symptom score.
The feasibility assessment suggested that a network could be constructed around those studies including similar baseline population characteristics and those measuring disease symptoms as a primary outcome. The focus of the network would be on those using the mB&B and those reporting the results of the mB&B using similar methodology (Figure 2 ).
Conclusions
The systematic literature review of the efficacy and safety of treatments for patients with moderate to severe symptomatic endometriosis-associated pain identified 62 studies for inclusion. However, due to poor reporting of study results and/or high risk of bias, over half of the studies had to be excluded. The most common outcome measure used to assess endometriosis-associated pain was the mB&B, therefore a network meta-analysis of GnRH analogues versus placebo or any other pharmacological treatment using this outcome variable was considered potentially feasible.
Comparison of new endometriosis treatments with existing GnRH analogues would be feasible if the trial data for the new treatments included similar baseline disease staging (rAFS classification) and similar outcome measures such as the modified B&B pain score and HRQoL assessment (SF-36 and EHP-30). 
